ZPDH:F:F-SPDR S&P U.S. Health Care Select Sector UCITS (EUR)

ETF | Others |

Last Closing

USD 41.67

Change

+0.34 (+0.81)%

Market Cap

USD 0.40B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-10 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

-0.19 (-0.68%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.36 (-0.69%)

USD 116.19B
SXR8:F iShares Core S&P 500 UCITS ETF..

-3.96 (-0.65%)

USD 109.51B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-0.35 (-0.62%)

USD 98.97B
XDNY:F Xtrackers MSCI Japan ESG Scree..

-0.24 (-1.51%)

USD 63.27B
SXRZ:F iShares VII PLC - iShares Nikk..

-1.85 (-0.76%)

USD 52.42B
VUSA:F Vanguard Funds Public Limited ..

-0.17 (-0.16%)

USD 51.63B
VUAA:F Vanguard S&P 500 UCITS Acc

N/A

USD 51.63B
XJSE:F Xtrackers II - Japan Governmen..

+0.01 (+0.17%)

USD 38.52B
0ZC:F Zscaler Inc

-0.40 (-0.22%)

USD 37.92B

ETFs Containing ZPDH:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.07% 86% B+ 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.07% 86% B+ 70% C-
Trailing 12 Months  
Capital Gain 8.52% 50% F 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.52% 46% F 48% F
Trailing 5 Years  
Capital Gain 57.96% 80% B- 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 57.96% 80% B- 58% F
Average Annual (5 Year Horizon)  
Capital Gain 12.63% 78% C+ 70% C-
Dividend Return 12.63% 76% C+ 63% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.84% 63% D 89% A-
Risk Adjusted Return 116.54% 98% N/A 98% N/A
Market Capitalization 0.40B 58% F 46% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike